Journal of the American Medical Association | January 12, 2023
This study found that Fluvoxamine, a drug used for psychiatric conditions with anti-inflammatory properties, did not reduce recovery time in patients with symptomatic mild to moderate COVID-19. These findings are important because it advances research into oral treatments for COVID-19 and directs clinicians to other avenues of treatment. Co-author Mario Castro, MD, MPH serves on the Lung Association Scientific Advisory Committee and is an ACRC investigator.
Join over 700,000 people who receive the latest news about lung health, including research, lung disease, air quality, quitting tobacco, inspiring stories and more!
Thank You!
You will now receive email updates from the American Lung Association.
Make a Donation
Your tax-deductible donation funds lung disease and lung cancer research, new treatments, lung health education, and more.
Join over 700,000 people who receive the latest news about lung health, including research, lung disease, air quality, quitting tobacco, inspiring stories and more!
Thank you! You will now receive email updates from the American Lung Association.
